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NDP001:
EXTENDED LYMPHADENECTOMY IMPROVES THE PROGNOSIS OF THE
PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: ANALYSIS
FROM THE NATIONWIDE CANCER REGISTRY DATABASE
Teng-Kai Yang 1, Chung-Hsin Chen 2, Wen-Jeng Wu3. 1 Surgery department,
Yonghe Cardinal Hospital, New Taipei city, Taiwan; 2Department of Urology,
National Taiwan University Hospital, Taipei, Taiwan; 3Kaohsiung Municipal
Ta-Tung Hospital, Kaohsiung, Taiwan
Purpose: This study was designed to assess the impact of the number of
dissected lymph nodes (LNs) on overall survival (OS) and cancer speciﬁc
survival (CSS) in patients undergoing radical cystectomy (RC) for bladder
cancer.
Materials and Methods: From 2008 to 2013, 289 patients undergoing RC
for treating muscle invasive bladder urothelial carcinoma staging T2-4N0
were selected from Taiwan cancer registry database. The number of
removed LNs, age, gender, pathological grade and stage, and pre-operative
image ﬁndings were assessed. The Cox proportional hazard model was
used to evaluate the impact of the number of removed LNs on overall
survival (OS) and cancer speciﬁc survival (CSS).
Results: After stratifying patients by the number of removed LNs, we
discovered there were no signiﬁcant differences of tumor stages, grade,
age, and gender. In multivariate regression models, after the adjust-
ment of age, gender, pathological grade and pathological stage, there
was a statistically signiﬁcant improvement OS (HR: 0.40; 95% CI:
0.20e0.82) and CSS (HR: 0.58; 95% CI: 0.36e0.92) in the patients who
had dissected LNs of more than 10 compared to those with fewer
dissected LNs.
Conclusion: In patients undergoing RC, dissected LNs of more than 10 was
associated with a signiﬁcantly better OS and CSS. That indicated an
extended lymphadenectomy would be helpful for improving patients’
prognosis.
NDP002:
PATIENTS WITH PATHOLOGICAL T3 PROSTATE CANCER TREATED WITH
ROBOT-ASSISTED RADICAL PROSTATECTOMY e A SINGLE INSTITUE
EXPERIENCE
Seng-Tang Wu, Chien-Chang Kao, Chu-Wei Tsao, Shou-Hung Tang, En
Meng, Guang-Huan Sun, Dah-Shyong Yu, Pao-Luo Fan, Sun-Yran Chang,
Tai-Lung Cha. Division of Urology, Department of Surgery, Tri-Service
General Hospital, National Defense Medical Center, Taipei, Taiwan
Purpose: We analyzed the surgical results of prostate cancer in patients
who had pT3 disease were treated by robot-assisted radical prostatectomy
(RARP) at our hospital.
Materials and Methods: There were over 500 prostate cancers had been
treated by RARP at our institution. We review 363 consecutive patients
who underwent RARP by a single surgeon from September 2009 to
February 2015. Peri- and post-operative data were collected and analyzed
for all patients.
Results: In total, 363 consecutive patients underwent RARP. Seven patients
with distant metastases at diagnosis, had neoadjuvant therapy and path-
ological T0 disease were excluded. Of these 356 patients, the mean agewas65.2 years, the mean pre-operative PSA was 10.2 ng/mL. 123 (34.6%) pa-
tients with mean age 65.9 and mean pre-operative PSA 13.9 ng/mL were
found to have pT3 disease, including pT3a in 80 and pT3b in 43 cases. The
PSM rate for patients with pT3 diseasewas 56.2%. The PSM rate for patients
with pT3a and pT3b disease was 51.3% and 39.5%, respectively. Comparing
pT3 with pT2 cases, the patient’s age, prostate weight were no different.
The pT3 group had higher mean pre-operative PSA level (13.4 vs 22.3 ng/
mL), percentage of tumor volume (14.4% vs 22.3%), positive margin rates
(9.9% vs 54.5%), biopsy and prostatectomy specimen Gleason score (6.7 vs
7.3, and 7.0 vs 7.4). 37 (30.1%) in 109 pT3 patients with biochemical
recurrence (BCR), time to BCR was 24 months. Biopsy Gleason score is the
only independent preoperative predictor of BCR in pT3a cases. Biopsy
Gleason and preoperative PSA are the only independent preoperative
predictors of BCR in pT3b RARP cases.
Conclusion: We present the results of the treatment for locally
advanced prostate cancer initially managed with RARP. Our ﬁndings
suggest that patients with locally advanced prostate cancer can be
treated with RARP with higher but acceptable positive margin rates and
surgical results.
NDP003:
TREND OF GLOBAL QUALITY OF LIFE IN LOCALIZED OR METASTATIC
PROSTATE CANCER PATIENTS AFTER TREATMENT
Yao-Lin Kao 1, Yuh-Shyan Tsai 1, Zong-Ying Lin 2, Chien-Hui Ou 1,
Wen-Horng Yang 1, Hong-Lin Chen 1, Tzong-Shin Tzai 1, Jung-Der Wang 2.
1Department of Urology, Medical College and Hospital, National Cheng
Kung University, Tainan, Taiwan; 2Department of Public Health, Medical
College and Hospital, National Cheng Kung University, Tainan, Taiwan
Purpose: Quality of life (QoL) is an important concern in prostate cancer
(PC) treatment, particularly facing with selection of any optimal therapy.
The trend of global QoL may help physician and patients in decision
making for treatment strategy. The aim of the study is to explore the trend
of global QoL after standard treatments in PC patients with localized or
metastatic diseases.
Materials and Methods: From January 2013 to April 2015, self-reported
questionnaires, World Health Organization Quality of Life-BREF (WHO-
QOL-BREF) serving as a tool for global QoL assessment with good validity
and reliability, were randomly obtained from prostate cancer patients at
urologic outpatient clinic. Repeated measurements in same individuals
were obtained from some individuals at different times during follow-up.
The mix-effect model was used for analyzing the determinant of global
QoL and a Kernel smoothing curve ﬁtting was used for analyzing the trend
of global QoL in the initial 5-year follow-up.
Results: A total of 287 patients and 526 person-times completed the
WHOQOL-BREF questionnaire with a mean age of 72.7 years, including
localized disease (n¼ 156) and metastatic disease (n¼ 131). The analysis
of the Kernel smooth curve showed decreases of global QoL in physical,
psychological and social domains in localized disease patients after
receiving radical prostatectomy or radiotherapy compare to active sur-
veillance group, both of which gradually recovered in one and half a year.
In contrast, metastatic patients exhibited both increases of global QoL in
physical and psychological domains after androgen deprivation therapy
or palliative radiotherapy as compared with watchful and supportive
groups (Figure 1). Moreover, radiotherapy is an independent risk factor
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months after radiotherapy, 0.017 and 0.004, respectively). There were
some limitations in this study, including single-institute and outpatient
alone.
Conclusion: During the initial 5-year follow-up, both radical prostatec-
tomy and radiotherapy had one-to-two year negative impacts on global
QoL in localized patients. Both hormonal therapy and palliative radio-
therapy had one-to-two year positive impacts on global QoL in metastatic
patients. Radiotherapy had a profound long-term decrease in sexual life
performance. These results can help physicians and patients in decision
making for optimal therapy.
NDP004:
ANALYSIS OF DETRUSOR MUSCLE SAMPLING DURING TRANSURETHRAL
RESECTION OF BLADDER TUMOR IN NON-MUSCLE INVASIVE BLADDER
CANCER
Yuan-Cheng Chu, See-Tong Pang, Ying-Hsu Chang, Cheng-Keng Chuang,
Po-Hung Lin, Chung-Yi Liu. Division of Urology, Department of Surgery,
Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan
Purpose: Transurethral resection of bladder tumor (TUR-BT) plays an
important role in the treatment and diagnosis of non-muscle invasive
bladder cancer (NMIBC). However, the pathology report of the bladder
tumor often had no detrusor muscle presentation. In this situation, it is
difﬁcult to decided the advanced treatment. Therefore, we analysis that
the detrusor muscle presentation inﬂuence the prognosis and the factors
affect the detrusor muscle presentation.
Materials and Methods: Retrospective review the pathology report of
TUR-BT from 2013 Jan. to 2013 Dec. in Chang Gung Memorial hospital in
Linkou. All patients was follow up for at least one-year.
Results: There are 150 patients underwent TUR-BT at Linkou CGMH in this
year. The NMIBC cases was about 100 (66.7%). The pathology report
showed detrusor muscle was 37% and no mention of detrusor muscle was
5%. Compared between the detrusor muscle present and the detrusor
muscle absent, the mortality rate within 1 year (0% v.s. 3%, p¼ 0.157) and
early recurrent rate (14% v.s. 12%, p> 0.05) had no signiﬁcant difference.
Besides, larger bladder tumor (>3cm, p¼ 0.037) and high-grade bladder
tumor (p¼ 0.018) had higher detrusor muscle presentation rate. Therewas
no difference in age (p¼ 0.298), gender (p¼ 0.454) and primary stage
(p¼ 0.383) in detrusor muscle presentation rate.
Conclusion: In this data, there was no obvious difference of prognosis
within 1 year, but need longer time of follow up to prove that. Pathol-
ogists rightly mention detrusor muscle when there is a higher proba-
bility of invasion. This help the clinic physician for further treatment
decision.
NDP005:
SEMI-RIGID URETEROSCOPY WITH THULLIUM LASER FOR THE
TREATMENT OF URETER UROTHELIAL CARCINOMA: EXPERIENCE OF
MACKAY MEMORIAL HOSPITAL
Ting-Po Lin. Department of Urology, Mackay Memorial Hospital, Taipei,
Taiwan
Purpose: Radical nephroureterectomy is the standard treatment of high
risk upper tract urothelial carcinoma (UTUC). However, renal-sparing
treatment as endoscopic ablation or segmental resection can be used
for low risk ureter urothelial carcinoma without compromising onco-
logical outcomes. In present study, we share the experience of using
semi-rigid uretersoscope with Thullium laser to treat ureter urothelial
carcinoma.
Materials and Methods: We retrospectively reviewed 9 cases with ureter
urothelial carcinoma managed by Thullium laser with semi-rigid ureter-
soscope from January 2014 to June 2015 in our hospital. Peri-operative
outcome and post-operative outcome were recorded.
Results: There are 9 patients underwent endoscopic treatment. Mean
(range) age was 67.1 (56~85) years old. Mean (range) follow up was 13.9
(3~22) months. Overall survival rate was 100%. Five patients received
endoscopic management due to low-risk tumor. Upper tract progression
or persisted carcinoma in situ was noted in three patients (60%), all ofthem received nephroureterectomy after then. Four patients received
endoscopic treatment because they are not suitable to nephroureter-
ectomy. All of the four patients with high risk or not suitable to neph-
roureterectomy had recurrence. No major complication was noted
perioperatively.
Conclusion: After endoscopic surgery, upper tract recurrence is common
even in low risk tumor. Regular surveillance with URS is needed. Salvage
nephroureterectomy is advised during close follow up.
NDP006:
COMPLEMENTARY TRADITIONAL CHINESE MEDICINE THERAPY
IMPROVES SURVIVAL IN PATIENTS WITH METASTATIC PROSTATE
CANCER
Jui-Ming Liu 1, Po-Hung Lin 2, Shun-Ku Lin 3, Ren-Jun Hsu 4. 1Division of
Urology, Department of Surgery Taoyuan General Hospital, Ministry of
Health and Welfare, Taiwan; 2Department of Urology, Chang Gung
Memorial Hospital, Taiwan; 3Department of Chinese medicine, Taipei City
Hospital, Ren-Ai Branch, Taiwan; 4Department of Pathology and Graduate
Institute of Pathology and Parasitology, the Tri-Service General Hospital,
National Defense Medical Center, Taipei, Taiwan
Purpose: More than 50% of prostate cancer patients have used traditional
Chinese medicine (TCM) in Taiwan. However, the long-term clinical efﬁ-
cacy of TCM in prostate cancer patients remains unclear. Here, we inves-
tigated the relationship between TCM use and the survival of prostate
cancer patients.
Materials and Methods: A retrospective nationwide cohort study of
prostate cancer patients was conducted between 1998 and 2003 using the
Taiwan National Health Insurance Research Database. The association
between death risk and TCM use was determined using Cox proportional
hazards models and Kaplan-Meier curves.
Results: Of the 1132 selected prostate cancer patients, 730 (64.5%) and 402
(35.5%) were TCM users and non-usrs, respectively. The mean follow-up
period was 8.38 years, and 292 (25.8%) deaths were reported. TCM users
had a decreased mortality rate (21.9%) compared to non-users (32.8%). A
lower death risk was observed with longer TCM use, especially in patients
who used TCM for S200 days (aHR, 0.61; 95% CI, 0.44e0.84). TCM users
with metastatic prostate cancer had a signiﬁcant lower hazard ratio than
non-users (aHR, 0.70; 95% CI, 0.51e0.95).
Conclusion: The result suggested that TCM might be associated with a
reduced risk of death in metastatic prostate cancer patients
NDP007:
UPPER URINARY TRACT TRANSITIONAL CANCER-THE EXPERIENCES IN
RECENT 5 YEARS AND LITERATURE REVIEW
Kuan-Tang Huang, Mao-sheng Lin. Department of Urology, Show-Chwan
Memorial Hospital, Changhua, Taiwan
Purpose: It has been shown that there are some difference of the distri-
bution of the upper urinary tract cancer between Taiwanese and other
races. Previous studies have shown an increased risk of upper urinary tract
urothelial carcinoma. We try to re-examine this risk.
Materials and Methods: We enrolled all 93 patients of upper urinary tract
cancer in Show-Chaun hospital in Chang-Hua Taiwan during 2008e2015,
and we retrospectively followed the development of cancer until 2012 by
analysis of data collected from the Taiwan Cancer Registry.
Results: There were 93 newly diagnosed cases of upper urological cancer
and most of them were transitional cell carcinoma (70.1%) and renal cell
carcinoma (28.0%). The mean age at diagnosis for upper urinary tract
cancer was 65.5 years. Focusing on urothelial carcinoma, when stratiﬁed
by location, there are 45.2% in renal pelvis, 32.6% in upper ureter and 20.4%
in both. About the tumor stage, there are 28.3% patients was stage I, 19.8%
was stage II, 35.0% was stage III and 16.9% was stage IV. The crude death
rate during 2008 to 2015 was 9.31% in stage I, 7.23% in stage II, 30.4% in
stage III and 66.7% in stage IV, respectively.
Conclusion: The urothelial carcinoma consisted the majority of upper
urinary tract cancer in Taiwan, followed by renal cell carcinoma. Most of
the urothelial carcinoma was located in the renal pelvis. It makes the
diagnosis more challengeable.
